Silver Book Fact

Identifying individuals at high risk for developing AFib

Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.

Schnabel R, Sullivan L, Levy D, Pencina M, et al. Development of a Risk Score for Atrial Fibrillation (Framingham Heart Study): A community-based cohort study. Lancet. 2009; 373(9665): 739-45. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2960443-8/abstract

Reference

Title
Development of a Risk Score for Atrial Fibrillation (Framingham Heart Study): A community-based cohort study
Publication
Lancet
Publication Date
2009
Authors
Schnabel R, Sullivan L, Levy D, Pencina M, et al
Volume & Issue
Volume 373, Issue 9665
Pages
739-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.  
  • Cost-savings associated with optimal anticoagulation in AFib patients
    If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Effects of optimal anticoagulation among AFib patients
    If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.  
  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…